2 not yet recruiting, 2 recruiting, 2 unknown, 1 terminated. 2 Not applicable, 2 Phase 1, 2 Phase 2, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Not applicable | 2 | Terminated 1, Withdrawn 1 |
| Phase 1 | 2 | Not yet recruiting 2 |
| Phase 2 | 2 | Not yet recruiting 1, Recruiting 1 |
| Phase 4 | 1 | Unknown 1 |
Follow Gynecological Tumors: new trials by email Literature Review of Gynecological Tumors trials Research Report on Gynecological Tumors
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of SI-B036 in Patients With Locally Advanced or Metastatic Gynecological Tumors and Other Solid Tumors SI-B036 - Gynecological Tumors, Solid Tumors | Phase 1 | Not yet recruiting | Sichuan Baili Pharmaceutical Co., Ltd. | 30 | 2026-09-01 | 2026-08-26 |
| A Study of BL-M08D1 in Patients With Recurrent or Metastatic Gynecological Malignancies and Other Solid Tumors BL-M08D1 - Gynecological Tumors, Solid Tumors | Phase 1 / Phase 2 | Not yet recruiting | Sichuan Baili Pharmaceutical Co., Ltd. | 90 | 2026-09-01 | 2026-08-31 |
| Gut Microbiome in Gynecological Cancer Patients With Pelvic Toxicity: Controls Versus Ozone Treatment. (MicrOzoGineTox) Pelvic Toxicity, Radiation Toxicity | Recruiting | Bernardino Clavo, MD, PhD | 38 | 2026-01-15 | 2026-09-23 | |
| A Clinical Trial of TQB2102 for Injection in Gynecological Tumors With Recurrent/Metastatic Advanced TQB2102 for injection - Gynecological Tumors | Phase 2 | Recruiting | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | 170 | 2025-03-13 | 2025-07-18 |
| Clinical Study of GT201 in the Treatment of Advanced Gynecological Tumors (Advanced Cervical Cancer) Autologous tumor infiltrating lymphocyte injection（GT201） - Adult, Gynecological Tumors | Not applicable | Terminated | Grit Biotechnology | 4 | 2023-06-05 | 2026-04-27 |
| Clinical Study of Autologous Tumor Infiltrating Lymphocyte Injection (GT316) in the Treatment of Advanced Solid Tumors (Gynecological Tumors) GT316 - Solid Tumor, Gynecological Tumors | Not applicable | Withdrawn | Grit Biotechnology | 2023-03-09 | 2026-04-29 | |
| Evaluation of the Diagnostic and Prognostic Role of PET (PET/CT and PET/MRI) in Gynecological Tumors. the diagnostic and prognostic value of PET/MRI and PET/CT with 18F-FDG in patients presenting with gynecological tumors - Gynecological Tumors | Unknown | IRCCS San Raffaele | 380 | 2021-10-27 | 2024-03-06 | |
| The Efficacy and Safety of PEG-rhG-CSF in Neutropenia After Chemotherapy PEG-rhG-CSF - Mammary Cancer, Lymphoma | Phase 4 | Unknown | Peking University | 217 | 2016-06-01 | 2016-09-19 |
Bone Neoplasms (1) · Breast Neoplasms (1) · Dysbiosis (1) · Lymphoma (1) · Radiation Injuries (1)
Bone Diseases (1) · Breast Diseases (1) · Hemic and Lymphatic Diseases (1) · Immune System Diseases (1) · Immunoproliferative Disorders (1) · Lymphatic Diseases (1) · Lymphoproliferative Disorders (1) · Musculoskeletal Diseases (1) · Neoplasms (1) · Neoplasms by Histologic Type (1) · Neoplasms by Site (1) · Pathologic Processes (1) · Pathological Conditions, Signs and Symptoms (1) · Skin Diseases (1) · Skin and Connective Tissue Diseases (1)
Injections (1) · Positron Emission Tomography Computed Tomography (1) · pegylated granulocyte colony-stimulating factor (1)
Grit Biotechnology (2) · Sichuan Baili Pharmaceutical Co., Ltd. (2) · Bernardino Clavo, MD, PhD (1) · Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. (1) · IRCCS San Raffaele (1) · Peking University (1)
China (5) · Italy (1) · Spain (1)
Bernardino Clavo, MD, PhD (1) · Jacob Lorenzo-Morales, Prof (1) · Jun Zhu, MD (1)